Immunology Market

Global Immunology Market is valued at USD 97.9 Billion in 2021 and is expected to reach USD 184.2 Billion by 2028 with a CAGR of 9.4% over the forecast period.

Global Immunology Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2022-2029: Rising Prevalence of Autoimmune Disorders and Increasing Novel Therapies are some of the major factors driving the growth of the Immunology Market.

Scope-

A crucial area of the medical and biological sciences, immunology is the study of the immune system. The  immune system defends us against infection via a number of different mechanisms. Diseases including cancer, allergies, and autoimmunity can develop if the immune system is not functioning  properly. Additionally, it is also becoming obvious that immunological responses play a role in the emergence of other prevalent disorders that are not often seen as immunologic, such as metabolic, cardiovascular, and neurodegenerative diseases like Alzheimer's.

COVID-19 Impact-

The COVID-19 epidemic had a negligible effect on immunology drug sales. As pharmaceutical companies considerably improved their supply chain management, expanded the capacity of their R&D, and increased investment in production management and quality control, a number of market participants did not report any decline in sales for items connected to this market.

For instance, AbbVie Inc. revealed that medicine sales in the financial year 2020 were up 13.2% from the previous year. Additionally, the company's immunology segment generated USD 25,284.0 million in 2021, up 14.1% from the previous year.

The COVID-19 pandemic, however, caused a reduction in income from these medications for a few businesses, including Merck & Co., Inc. Due to this, market growth was  slower in 2019 and 2020. Additionally, the stagnant market expansion can also be partly attributed to the recent loss of patent protection for popular drugs, the delaying of regulatory approvals for new medications, the increased use of biosimilars during the pandemic, and the postponed or canceled patient visits to hospitals and clinics.

For instance,  a research published by NCBI in 2020 found that during the COVID-19 pandemic, a total of 376 rheumatoid arthritis patients had 43.6% of visits missed more than once and a 17.2% no-show rate. However, it is predicted that the immunology market would develop during the forecast period due to the increased consumption of immunology medicines in 2021 as well as an increase in the number of drug approvals and launches.

Key Players-

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Janssen Global Services LLC
• Eli Lilly and Company
• Novartis AG
• Merck Sharp & Dohme Corp.
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Amgen Inc.
• Astellas Pharma Inc.
• UCB SA

Segmentation-

By Drug Class:

• Monoclonal Antibody (mAb)
• Fusion Proteins
• Immunosuppressants
• Polyclonal Antibody (pAb)
• Others

By Disease Indication:

• Rheumatoid Arthritis
• Psoriatic Arthritis
• Plaque Psoriasis
• Ankylosing Spondylitis
• Inflammatory Bowel Disease
• Prophylaxis of Organ Rejection
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Regional & Country Level:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Market Drivers-

Rising Prevalence of Autoimmune Disorders and Increasing Novel Therapies are Expected to Boost Immunology Market Growth:

A high proportion of individuals with autoimmune illnesses are caused by a variety of causes, such as infections, stress, dietary components, gut dysbiosis, and exposure to hazardous substances. Around 50 million Americans currently have at least one kind of autoimmune disease, making autoimmune disorders the third most common chronic condition in the nation. For instance, according to a study by the National Stem Cell Foundation, at least one of 80 or more autoimmune illnesses affects around 4% of the global population.

The market participants are working extremely hard to develop and introduce new products to the market as a result of the growing demand for these medications among patients. The pipeline portfolios of the major companies in the immunology market are thus expanding rapidly. As of April 2022, for instance, Johnson & Johnson Services, Inc. had over 20 pipeline candidates for diverse autoimmune indications such as inflammatory bowel disease, psoriatic arthritis, and rheumatoid arthritis, while Sanofi had about 30 pipeline projects in the immunology division.

For instance, Lupin introduced Leflunomide, a generic rheumatoid arthritis medication, in the United States in September 2020. This product is anticipated to fuel market expansion during the course of the projection year. Additionally, it is predicted that the market would rise during the forecast period due to growing awareness of autoimmune illnesses in both developed and developing countries as well as prospective pipeline prospects.

Market Restraints-

High Costs Associated with Treatment and Adverse Effects Associated with the Product are expected to Hinder Immunology Market Growth:

Despite the rising frequency of immunological illnesses in important countries, the market's expansion is restricted during the projected period by factors such as the treatments' high cost and unfavorable side effects. Biopharmaceuticals are expensive, in particular, due to the high cost of the manufacturing facilities and the significant investment in research and development required to get biologics through FDA clearance and clinical trial procedures.

For instance, only 10-20% of pharmaceuticals examined during the research stage are effective and reach the market, according to a 2020 study article published by Springer Nature. As a result, the manufacturing of new drugs costs around USD 3.00 billion. These medications are also associated with a variety of negative side effects, including fever, fast/irregular/pounding heartbeat, infections, allergy symptoms, muscular pains, and allergic reactions.

As a result, the market expansion during the research period was hindered by the aforementioned factor as well as the restrictive compensation regulations in developing nations.

Geography Analysis-

North America is expected to Capture a Major Share of the Global Immunology Market:

In 2021, North America generated US$54.04 billion in sales. The region had a dominant market share in immunology and is anticipated to expand at a considerable CAGR during the forecast period. The United States' dominance in the global market may be attributed to the higher prevalence of chronic diseases, the presence of sophisticated healthcare infrastructure, and the development of patient diagnostic and treatment rates.

Europe Immunology Market Is Expected to Grow at A significant Pace Over the Forecast Period:

The rising prevalence of autoimmune diseases and the rising number of medication approvals in Europe are likely to contribute to the continent's significant CAGR throughout the projection period. For instance, a 2021 article on autoimmune disorders from the University of London estimates that 7% of the U.K. population, or over 4 million individuals, have at least one autoimmune disorder.

Asia Pacific Immunology Market Is Expected to Grow at A Considerable Pace Over The Forecast Period:

Due to the vast population of patients with autoimmune illnesses and the rising need for preventative care, the market in the Asia Pacific is predicted to expand at a higher CAGR. Additionally, throughout the projection period, major companies are expected to increase their efforts to advance the approval and introduction of medications for autoimmune diseases. For instance, the Japanese Ministry of Health, Labor, and Welfare granted UCB S.A. marketing approval for BIMZELX to treat plaque psoriasis in January 2022.

News-

• Pfizer acquired Arena Pharmaceuticals in February 2022. To diversify its therapeutic immunology portfolio, this clinical-stage company created novel potential treatments for treating a number of immune inflammatory disorders.
• OLUMIANT a systemic first-in-disease therapy for individuals with severe alopecia areata (AA), by Eli Lilly and Company, was approved by the U.S. FDA in June 2022.
• RINVOQ by AbbVie Inc. was given FDA clearance by the U.S. in April 2022 to treat people with active ankylosing spondylitis.
• The U.S. FDA approved Rinvoq (by AbbVie Inc.) for the treatment of moderately to highly active ulcerative colitis in adults in March 2022.
• In March 2022 Pfizer Inc., a business that creates cutting-edge prospective medicines for the management of a number of immuno-inflammatory illnesses acquired Arena Pharmaceuticals to strengthen its Immunology Portfolio.
• AbbVie announced in October 2022 that it had acquired DJS Antibodies Ltd., a private biotechnology company based in the UK, with the goal of concentrating on building up the body of antibodies that cause incurable diseases and discovering antibodies with specific capabilities targeting transmembrane protein targets, such as G-protein–coupled receptors. Pre - clinical research is now being conducted on a possible lysophosphatidic acid (LPA) receptor 1 (LPAR1) antagonist antibody for the treatment of idiopathic pulmonary fibrosis (IPF), an aggressive condition with a high death rate spurred on by fibrotic scarring in the lungs.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2021:	USD 97.9 Billion
Base year considered	2021
Forecast Period CAGR %:	9.4%
Market Size Expected in 2028:	USD 184.2 Billion
Tables, Charts & Figures:	175
Pages	300
Companies	AbbVie, Inc., F. Hoffmann-La Roche Ltd., Janssen Global Services, LLC, Eli Lilly, and Company, Novartis AG, Merck Sharp & Dohme Corp., Pfizer Inc., Bristol-Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., and UCB SA
Segments Covered	By Drug Class, By Disease Indication, By Distribution Channel
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa